FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954585928> ?p ?o ?g. }

• W2954585928 endingPage "CT219" @default.
• W2954585928 startingPage "CT219" @default.
• W2954585928 abstract "Abstract BACKGROUND: The combination of a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) with an aromatase inhibitor (AI) significantly reduces Ki67 compared to single-agent AI in the neoadjuvant setting, but the rates of pathological complete response (pCR) or residual cancer burden (RCB) 0-I remain modest. Despite this inadequate pathological downstaging, to date, there is no data about the efficacy of this treatment in terms of molecular downstaging detected by a more refined genomic signature than Ki67, such as the Oncotype DX Breast Recurrence Score® (RS) test. The aim of this trial is to validate the ability of neoadjuvant palbociclib plus letrozole to modify two initial intermediate or high RS tumor cohorts. TRIAL DESIGN: This is an international, multicenter, open-label, non-comparative, phase II trial. Main selection criteria include: (1) Pre- or post-menopausal women with treatment-naïve, centrally assessed, HR-positive/HER2-negative, Ki67 ≥ 20%, and stage II-IIIB breast cancer; (2) Pre-treatment RS result ≥ 18; (3) Patients agree to collect tissue samples at screening, at Cycle 1 Day 14 of treatment, and at surgery. Patients will be allocated, according to the pre-treatment RS result, either to Cohort A (RS 18-25) or Cohort B (RS 26-100) and will receive treatment with palbociclib (125 mg QD, 3/1 schedule) in combination with letrozole (2.5 mg QD, every 28-day cycle), ± LHRH analogs if pre-menopausal status, for 24 weeks. Definitive breast surgery will be performed within 7 days after completion of 6 treatment cycles. The primary objective of the study is to explore the ability of palbociclib in combination with letrozole to induce global molecular changes, measured by either the post-treatment RS result at surgery, or pCR. Secondary objectives include: (1) Concordance rate among post-treatment RS result and RCB, Ki67, and preoperative endocrine prognostic index (PEPI) score; (2) Overall response rate; (3) Safety-related outcome as per Common Terminology Criteria for Adverse Events v. 5.0. Patients will be accrued in a Simon’s two-stage design trial: optimal design in Cohort A and minimax design in Cohort B. With a unilateral type one error (alpha) set at 0.025 and a 0.8 power (type two error beta = 0.2), the required number of evaluable patients are 28. Considering a drop-out rate no lower than 10%, a sample size of 33 patients in each cohort will be needed. First Patient First Visit: Expected on April 2019. Citation Format: Antonio Llombart Cussac, José Pérez-García, Ángel Guerrero, Begoña Bermejo, Miguel Gil, Vicente Carañana, Serafín Morales, Juan de la Haba, María Fernández, Emilio Alba, Ander Urruticoechea, Lourdes Calvo, Mireia Margeli, Antonio Antón, Manuel Ruíz Borrego, Joan Albanell, Pedro Sánchez Rovira, Meritxell Bellet, Sofia Braga, Passos Coelho, Miguel Abreu, Javier Cortés. Neoadjuvant letrozole and palbociclib in stage II-IIIB HR[+]/HER2[-] breast cancer with Oncotype DX Recurrence Score® (RS) 18-25 or 26-100. Analysis of RS changes at surgery (DxCARTES trial) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT219." @default.
• W2954585928 created "2019-07-12" @default.
• W2954585928 creator A5018922989 @default.
• W2954585928 creator A5020462811 @default.
• W2954585928 creator A5024784028 @default.
• W2954585928 creator A5025238669 @default.
• W2954585928 creator A5029048001 @default.
• W2954585928 creator A5030451537 @default.
• W2954585928 creator A5032621510 @default.
• W2954585928 creator A5036532311 @default.
• W2954585928 creator A5040158829 @default.
• W2954585928 creator A5051629490 @default.
• W2954585928 creator A5059814605 @default.
• W2954585928 creator A5065072315 @default.
• W2954585928 creator A5068052689 @default.
• W2954585928 creator A5069572905 @default.
• W2954585928 creator A5071164705 @default.
• W2954585928 creator A5080309829 @default.
• W2954585928 creator A5081859210 @default.
• W2954585928 creator A5084820259 @default.
• W2954585928 creator A5085797367 @default.
• W2954585928 creator A5090108117 @default.
• W2954585928 creator A5090790623 @default.
• W2954585928 creator A5091257174 @default.
• W2954585928 date "2019-07-01" @default.
• W2954585928 modified "2023-10-16" @default.
• W2954585928 title "Abstract CT219: Neoadjuvant letrozole and palbociclib in stage II-IIIB HR[+]/HER2[-] breast cancer with Oncotype DX Recurrence Score® (RS) 18-25 or 26-100. Analysis of RS changes at surgery (DxCARTES trial)" @default.
• W2954585928 doi "https://doi.org/10.1158/1538-7445.am2019-ct219" @default.
• W2954585928 hasPublicationYear "2019" @default.
• W2954585928 type Work @default.
• W2954585928 sameAs 2954585928 @default.
• W2954585928 citedByCount "4" @default.
• W2954585928 countsByYear W29545859282021 @default.
• W2954585928 countsByYear W29545859282022 @default.
• W2954585928 countsByYear W29545859282023 @default.
• W2954585928 crossrefType "journal-article" @default.
• W2954585928 hasAuthorship W2954585928A5018922989 @default.
• W2954585928 hasAuthorship W2954585928A5020462811 @default.
• W2954585928 hasAuthorship W2954585928A5024784028 @default.
• W2954585928 hasAuthorship W2954585928A5025238669 @default.
• W2954585928 hasAuthorship W2954585928A5029048001 @default.
• W2954585928 hasAuthorship W2954585928A5030451537 @default.
• W2954585928 hasAuthorship W2954585928A5032621510 @default.
• W2954585928 hasAuthorship W2954585928A5036532311 @default.
• W2954585928 hasAuthorship W2954585928A5040158829 @default.
• W2954585928 hasAuthorship W2954585928A5051629490 @default.
• W2954585928 hasAuthorship W2954585928A5059814605 @default.
• W2954585928 hasAuthorship W2954585928A5065072315 @default.
• W2954585928 hasAuthorship W2954585928A5068052689 @default.
• W2954585928 hasAuthorship W2954585928A5069572905 @default.
• W2954585928 hasAuthorship W2954585928A5071164705 @default.
• W2954585928 hasAuthorship W2954585928A5080309829 @default.
• W2954585928 hasAuthorship W2954585928A5081859210 @default.
• W2954585928 hasAuthorship W2954585928A5084820259 @default.
• W2954585928 hasAuthorship W2954585928A5085797367 @default.
• W2954585928 hasAuthorship W2954585928A5090108117 @default.
• W2954585928 hasAuthorship W2954585928A5090790623 @default.
• W2954585928 hasAuthorship W2954585928A5091257174 @default.
• W2954585928 hasConcept C121608353 @default.
• W2954585928 hasConcept C126322002 @default.
• W2954585928 hasConcept C126894567 @default.
• W2954585928 hasConcept C143998085 @default.
• W2954585928 hasConcept C146357865 @default.
• W2954585928 hasConcept C151730666 @default.
• W2954585928 hasConcept C2775930923 @default.
• W2954585928 hasConcept C2776166826 @default.
• W2954585928 hasConcept C2778292576 @default.
• W2954585928 hasConcept C2778504769 @default.
• W2954585928 hasConcept C2778812593 @default.
• W2954585928 hasConcept C2779744173 @default.
• W2954585928 hasConcept C29456083 @default.
• W2954585928 hasConcept C530470458 @default.
• W2954585928 hasConcept C71924100 @default.
• W2954585928 hasConcept C72563966 @default.
• W2954585928 hasConcept C86803240 @default.
• W2954585928 hasConceptScore W2954585928C121608353 @default.
• W2954585928 hasConceptScore W2954585928C126322002 @default.
• W2954585928 hasConceptScore W2954585928C126894567 @default.
• W2954585928 hasConceptScore W2954585928C143998085 @default.
• W2954585928 hasConceptScore W2954585928C146357865 @default.
• W2954585928 hasConceptScore W2954585928C151730666 @default.
• W2954585928 hasConceptScore W2954585928C2775930923 @default.
• W2954585928 hasConceptScore W2954585928C2776166826 @default.
• W2954585928 hasConceptScore W2954585928C2778292576 @default.
• W2954585928 hasConceptScore W2954585928C2778504769 @default.
• W2954585928 hasConceptScore W2954585928C2778812593 @default.
• W2954585928 hasConceptScore W2954585928C2779744173 @default.
• W2954585928 hasConceptScore W2954585928C29456083 @default.
• W2954585928 hasConceptScore W2954585928C530470458 @default.
• W2954585928 hasConceptScore W2954585928C71924100 @default.
• W2954585928 hasConceptScore W2954585928C72563966 @default.
• W2954585928 hasConceptScore W2954585928C86803240 @default.
• W2954585928 hasIssue "13_Supplement" @default.
• W2954585928 hasLocation W29545859281 @default.
• W2954585928 hasOpenAccess W2954585928 @default.
• W2954585928 hasPrimaryLocation W29545859281 @default.
• W2954585928 hasRelatedWork W1496249355 @default.
• W2954585928 hasRelatedWork W1971410221 @default.

• next